Telmisartan Inhibits Cell Proliferation by Blocking Nuclear Translocation of ProHB-EGF C-Terminal Fragment in Colon Cancer Cells

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Ozeki, Keiji ^a   Tanida, Satoshi ^a   Morimoto, Chie ^b   Inoue, Yoshimasa ^c   Mizoshita, Tsutomu ^a   Tsukamoto, Hironobu ^a   Shimura, Takaya ^a   Kataoka, Hiromi ^a   Kamiya, Takeshi ^a   Nishiwaki, Eiji ^c   Ishiguro, Hiroshi ^d   Higashiyama, Shigeki ^e,f   Joh, Takashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Matsuyama Shinonome Junior College   (Japan)

^c 1 5 5 Minatojima Minamimachi   (Japan)

^d GIFU UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^e EHIME UNIVERSITY   (Japan)

^f EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ANGIOTENSIN 1 RECEPTOR; CANDESARTAN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; PHORBOL 13 ACETATE 12 MYRISTATE; PROHEPARIN BINDING EPIDERMAL GROWTH FACTOR; PROMYELOCYTIC LEUKEMIA ZINC FINGER PROTEIN; TELMISARTAN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; COLON CANCER; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; GROWTH CURVE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

BENZIMIDAZOLES; BENZOATES; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; COLONIC NEOPLASMS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PHORBOL ESTERS; PROTEIN TRANSPORT;

EID: 84874340223     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056770     Document Type: Article

References (27)

1. Saika K, Machii R, (2011) Time trends in colon, rectum and anus cancer mortality between 1955 and 2008 in Japan, USA and Europe based on the WHO mortality database. Jpn J Clin Oncol 41: 1153.
2. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345.
3. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417.
4. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
5. Yotsumoto F, Yagi H, Suzuki SO, Oki E, Tsujioka H, et al. (2008) Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 365: 555-561.
6. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M, (1991) A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251: 936-939.
7. Yoshida M, Shimura T, Sato M, Ebi M, Nakazawa T, et al. (2012) A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. J Cancer Res Clin Oncol.
8. Kopp R, Rothbauer E, Ruge M, Arnholdt H, Spranger J, et al. (2003) Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res 162: 115-132.
9. Wang F, Liu R, Lee SW, Sloss CM, Couget J, et al. (2007) Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 26: 2006-2016.
10. Goishi K, Higashiyama S, Klagsbrun M, Nakano N, Umata T, et al. (1995) Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol Biol Cell 6: 967-980.
11. Tanida S, Joh T, Itoh K, Kataoka H, Sasaki M, et al. (2004) The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells. Gastroenterology 127: 559-569.
12. Nanba D, Mammoto A, Hashimoto K, Higashiyama S, (2003) Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 163: 489-502.
13. Hieda M, Isokane M, Koizumi M, Higashi C, Tachibana T, et al. (2008) Membrane-anchored growth factor, HB-EGF, on the cell surface targeted to the inner nuclear membrane. J Cell Biol 180: 763-769.
14. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, et al. (2002) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8: 35-40.
15. Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, et al. (2006) Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res 72: 184-190.
16. Yoshida T, Yamagishi S, Nakamura K, Matsui T, Imaizumi T, et al. (2006) Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 49: 3094-3099.
17. Hashimoto K, Higashiyama S, Asada H, Hashimura E, Kobayashi T, et al. (1994) Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J Biol Chem 269: 20060-20066.
18. Kinney EL, Tanida S, Rodrigue AA, Johnson JK, Tompkins VS, et al. (2008) Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1-dependent mechanism. J Cell Physiol 216: 621-631.
19. Tanida S, Kataoka H, Mizoshita T, Shimura T, Kamiya T, et al. (2010) Intranuclear translocation signaling of HB-EGF carboxy-terminal fragment and mucosal defense through cell proliferation and migration in digestive tracts. Digestion 82: 145-149.
20. Schupp M, Janke J, Clasen R, Unger T, Kintscher U, (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109: 2054-2057.
21. Funao K, Matsuyama M, Kawahito Y, Sano H, Chargui J, et al. (2008) Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol Rep 20: 295-300.
22. Shimura T, Yoshida M, Fukuda S, Ebi M, Hirata Y, et al. (2012) Nuclear translocation of the cytoplasmic domain of HB-EGF induces gastric cancer invasion. BMC Cancer 12: 205.
23. Shimura T, Kataoka H, Ogasawara N, Kubota E, Sasaki M, et al. (2008) Suppression of proHB-EGF carboxy-terminal fragment nuclear translocation: a new molecular target therapy for gastric cancer. Clin Cancer Res 14: 3956-3965.
24. Wienen W, (2000) A review on telmisartan: A novel, long-acting angiotensin II-receptor antagonist. Cardiovascular Drug Reviews 18: 127-156.
25. Isobe A, Takeda T, Sakata M, Miyake A, Yamamoto T, et al. (2008) Dual repressive effect of angiotensin II-type 1 receptor blocker telmisartan on angiotensin II-induced and estradiol-induced uterine leiomyoma cell proliferation. Hum Reprod 23: 440-446.
26. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A, (2002) Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 50: 658-664.
27. Teo KK, (2011) Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens 29: 623-635.